Neutralizing antibodies against IFN beta in patients with multiple sclerosis: A comparative study of two cytopathic effect tests (CPE) for their detection

Journal of Immunological Methods

Volumn 351, Issue 1-2, 2009, Pages 41-45

  Oliver, B ^a   Orpez T ^a   Mayorga, C ^a   Pinto Medel, M J ^a   Leyva, L ^a   Lopez Gomez C ^a   Marin C ^a   Luque, G ^a   Ortega Pinazo, J ^a   Fernandez O ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

A549 EMCV; Bioassay; Cytopathic effect method (CPE); HEP2 VSV; Interferon beta treatment; Neutralizing antibodies (NABs)

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY;

ANTIBODY DETECTION; ARTICLE; BIOASSAY; CANCER CELL CULTURE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; ENCEPHALOMYOCARDITIS VIRUS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; VALIDITY; VESICULAR STOMATITIS VIRUS;

ANIMALS; ANTIBODIES, BLOCKING; APOPTOSIS; CARDIOVIRUS INFECTIONS; CELL LINE, TUMOR; CYTOPATHOGENIC EFFECT, VIRAL; ENCEPHALOMYOCARDITIS VIRUS; HUMANS; INTERFERON-BETA; MICE; MULTIPLE SCLEROSIS; PRACTICE GUIDELINES AS TOPIC; RESPIRATORY MUCOSA; RHABDOVIRIDAE INFECTIONS; SENSITIVITY AND SPECIFICITY; SEROLOGIC TESTS; VESICULAR STOMATITIS INDIANA VIRUS; WORLD HEALTH ORGANIZATION;

ENCEPHALOMYOCARDITIS VIRUS; MURINAE;

EID: 70350616193     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2009.09.005     Document Type: Article

References (25)

1. Antonetti F., Finocchiaro O., Mascia M., Terlizzese M.G., and Jaber A. A comparison of the biologic activity of two recombinant IFN-beta preparations used in the treatment of relapsing-remitting multiple sclerosis. J. Interferon Cytokine Res. 22 12 (2002) 1181 Dec
2. Bertolotto F., and Gilli. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 60 (2003) 634
3. Bertolotto, A., Malucchi, S., Sala, A., Orefice, G., Carrieri, P.B., Capobianco, M., Milano, E., Melis, F., Giordana, M.T., 2002. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J. Neurol. Neurosurg. Psychiatry 73 (2),148 Aug.
4. Fernandez-Fernandez O., Fernandez-Sanchez V.E., Mayorga C., Guerrero-Fernandez M., Leon A., Tamayo-Toledo J.A., Alonso A., Romero F., Leyva L., Luque G., and de Ramon E. Interferon-beta response in multiple sclerosis associated with pre-treatment disability. Rev. Neurol. 43 6 (2006) 322 Sept. 16-30
5. Grossberg S.E., and Kawade Y. The expression of potency of neutralizing antibodies for interferons and other cytokines. Biotherapy 10 1 (1997) 93
6. Grossberg S.E., Kawade Y., Kohase M., and Klein J.P. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J. Interferon Cytokine Res. 21 9 (2001) 743 Sep
7. Hesse, D., Sørensen, P.S., 2007. Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy. Eur. J. Neurol. 14 (8), 850 Aug. Review.
8. Kawade Y., Finter N., and Grossberg S.E. Neutralization of the biological activity of cytokines and other protein effectors by antibody: theoretical formulation of antibody titration curves in relation to antibody affinity. J. Immunol. Methods 278 1-2 (2003) 127 Jul
9. Massart, C., Gibassier, J., Oger, J., Le Page, E., Edan, G., 2007. Neutralizing antibodies to interferon beta in multiple sclerosis: analytical evaluation for validation of a cytopathic effect assay. Clin. Chim. Acta. 377 (1-2) 185-91 Feb. Electronic publication ahead of print 2006 Sep 30. Erratum in: Clin. Chim. Acta. 380 (1-2), 255 May.
10. McKay F., Schibeci S., Heard R., Stewart G., and Booth D. Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australasian cohort. J. Immunol. Methods 310 1-2 (2006) 20 Mar 20, Dec 20
11. Pachner A., Narayan K., Price N., Hurd M., and Dail D. MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. Mol. Diagn. 7 1 (2003) 17
12. Pachner A.R., Bertolotto A., and Deisenhammer F. Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB). Neurology 61 9 Suppl 5 (2003) S24 Nov 11
13. Pachner A.R., Dail D., Pak E., and Narayan K. The importance of measuring IFNβ bioactivity: monitoring in MS patients and the effect. J. Neuroimmunol. 166 1-2 (2005) 180 Sep
14. Panitch H., Goodin D.S., Francis G., Chang P., Coyle P.K., O'Connor P., Monaghan E., Li D., Weinshenker B., and EVIDENCE Study Group. Evidence of interferon dose-response: Europian North American Compartative Efficacy; University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology 59 10 (2002) 1496 Nov 26
15. Pharm Res. Apr;15(4):641-9.
16. Phillips J.T., Rice G., Frohman E., Van de Gaer L., Scott T., Haas J., Eggenberger E., Freedman M.S., Stuart W., Cunha L., Jacobs L., Oger J., Arnold D., Murray T.J., DiBiase M., Jethwa V., and Goelz S. A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis. Clin. Ther. 26 4 (2004) 511 Apr
17. Rudick R.A., Simonian N.A., Alam J.A., Campion M., Scaramucci J.O., Jones W., Coats M.E., Goodkin D.E., Weinstock-Guttman B., Herndon R.M., et al., and the Multiple Sclerosis Collaborative Research Group (MSCRG). Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 50 (1998) 1266
18. Rudick R.A., Simonian N.A., Alam J.A., Campion M., Scaramucci J.O., Jones W., Coats M.E., Goodkin D.E., Weinstock-Guttman B., Herndon R.M., Mass M.K., Richert J.R., Salazar A.M., Munschauer III F.E., Cookfair D.L., Simon J.H., and Jacobs L.D. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 50 5 (1998) 1266 May
19. Runkel L., Meier W., Pepinsky R.B., Karpusas M., Whitty A., Kimball K., Brickelmaier M., Muldowney C., Jones W., and Goelz S.E. Structural and Functional Differences Between Glycosylated and Non-glycosylated Forms of Human Interferon-beta (IFN-beta) (1998)
20. Sorensen P.S., Ross C., Clemmesen K.M., Bendtzen K., Frederiksen J.L., Jensen K., Kristensen O., Petersen T., Rasmussen S., Ravnborg M., Stenager E., Koch-Henriksen N., and Danish Multiple Sclerosis Study Group. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362 9391 (2003) 1184 Oct 11
21. Sorensen P.S., Koch-Henriksen N., Ross C., Clemmesen K.M., Bendtzen K., and and the Danish Multiple Sclerosis Study Group. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 65 (2005) 33
22. Sorensen P.S., Tscherning T., Mathiesen H.K., Langkilde A.R., Ross C., Ravnborg M., and Bendtzen K. Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS. Neurology 67 9 (2006) 1681-3 Nov. 14
23. Sørensen P.S., Deisenhammer F., Duda P., Hohlfeld R., Myhr K.M., Palace J., Polman C., Pozzilli C., and Ross C. EFNS Task Force on Anti-IFN-beta Antibodies in Multiple Sclerosis Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur. J. Neurol. 12 11 (2005) 817 Nov
24. Trapp B.D., Peterson J., Ransohoff R.M., et al. Axonal transection in the lesions of multiple sclerosis. New Engl. J. Med. 338 (1998) 278
25. WHO Expert Committee on Biological Standardisation. Thirty-Fifth Report. WHO Technical Report Series vol. 725 (1985), World Health Organization, Geneva